Hamilton Highlights Newsletter – July 2018
In the July edition of Hamilton Highlights…
- Celebrate the first-ever Hamilton Newcomer Day on July 27, 2018
- Hamilton Helps Move Project Forward
- Hamilton Health Sciences Featured in Globe and Mail
- Tourism Hamilton Welcomes 61st Canusa Games Back to Hamilton
- Government Funding for Steel and Aluminum Business Investments
- Major Development in Downtown Hamilton
Canada’s science minister announces $10.5 million federal boost for McMaster research commercialization
McMaster’s Centre for Probe Development and Commercialization, which converts research on medical isotopes into new diagnostic tests and cancer treatments, has received a significant boost in the form of $10.5 million in federal funding.
Canada’s Minister of Science and Sport Kirsty Duncan visited the university’s commercialization hub at McMaster Innovation Park to announce a total of $79.8 million in federal funding for five National Centres of Excellence for Commercialization and Research across the country, including McMaster’s CPDC.
“Today we are investing in science for healthier communities,” Duncan said. “The five research centres awarded today mobilize Canada’s best research, development and entrepreneurial talent to transform new discoveries into concrete products, services and processes to improve our lives.”
The four-year commitment to McMaster’s CPDC makes it the only National Centre of Excellence for Commercialization and Research to receive three rounds of federal funding.
“We are grateful for this investment and proud to have this opportunity to prove that our discoveries can be scaled up to improve human health while also creating important, high-quality employment,” says Karen Mossman, McMaster’s acting Vice President, Research.
The federal funding, together with continuing funding from the Ontario Institute for Cancer Research and industrial partners, is expected to propel the CPDC through the critical next four years of its operation, which includes working with leading private sector and academic partners to develop and manufacture radiopharmaceuticals – an emerging class of diagnostic tests and treatments for diseases that include cancer and heart disorders.
“This funding is a welcome affirmation of the impact and quality of the work by the talented staff at the CPDC,” said CPDC founder John Valliant, a professor of Chemistry and Chemical Biology at McMaster. “The CPDC is attracting significant private-sector investment in Canadian science and creating new high-tech jobs while providing products that help patients every single day. This is possible because of the support of government, industry and McMaster itself, which promotes innovative research, education and commercialization.”
The CPDC, located on the west part of McMaster’s main campus, has created spinoff companies that include two in Hamilton: Fusion Pharmaceuticals and NuGeneris Inc.
Both companies will be co-located with the Fraunhofer Project Centre for Biomedical Engineering and Advanced Manufacturing at McMaster, and other emerging biotech commercialization initiatives, in an environment designed to facilitate mutual success.
The funding will be used to translate and commercialize new radiopharmaceuticals with particular emphasis on products developed from therapeutic medical isotopes. Through innovative local, national and international partnerships, and by creating learning opportunities for young entrepreneurs, CPDC will create new businesses and employment opportunities. By the end of the funding period, the aim is for CPDC and its spin out companies to support as many as 200 jobs.
Minister Duncan announced five grants, totaling $79.8 million, to be delivered through the Centres of Excellence for Commercialization and Research (CECR) program. The five hubs are located in Hamilton and Toronto, Ontario; Montreal, Quebec; and St. John’s, Newfoundland.
Article courtesy of McMaster University
Ontario’s Hamilton Health Sciences developing healthcare AI applications
Ontario medical group Hamilton Health Sciences has announced a partnership with clinician company Real Time Medical on artificial intelligence (AI) application development for healthcare.
Real Time Medical will work with Hamilton Health Sciences and MIIRCAM (Medical Imagining Informatics Research Centre at McMaster) on the following services:
- Advanced research and collaboration on new projects
- AI training
- Clinical trials and leadership and advisory services
- Data labeling and validation
- Identification of the most beneficial clinical applications
- Joint IP development and patenting
- Provision of various balancing technology for use during validation and clinical trials
- Validation of resulting algorithms with over a hundred 100 licensed radiologists
“The development and validation of algorithms using high quality, well correlated clinical data sets is still very much a challenge for AI application initiatives,” said Dr. David Koff, chair of the Department of Radiology, McMaster University Hospital, of the need for the new partnership. According to Hamilton Health Sciences, the collaboration will bring together AI technology developers and close to 100 faculty, 32 residents and 12 fellows, medical physicists and engineering resources.
Article courtesy of Bradley Shankar, BetaKit